within Pharmacolibrary.Drugs.ATC.L;

model L01XA05
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0008333333333333334,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.01,
    k12             = 300,
    k21             = 300
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XA05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Polyplatillen is a platinum-based antineoplastic agent used in the treatment of various cancers, such as ovarian cancer. It belongs to the class of alkylating agents (L01XA) and acts mainly through the crosslinking of DNA, inhibiting DNA synthesis and inducing apoptosis in tumor cells. Polyplatillen is not widely used or approved today; historical use has been reported, but it has largely been replaced by newer platinum compounds with more favorable toxicity profiles.</p><h4>Pharmacokinetics</h4><p>No pharmacokinetic parameters for polyplatillen were found in published literature as of June 2024. The following represents an estimated typical PK model for a platinum-based drug administered intravenously in adult cancer patients. All PK parameters are approximate and extrapolated from the general properties of this drug class.</p><h4>References</h4><ol><li><p>Bartelink, H, et al., &amp; Verheij, M (2000). Translational research offers individually tailored treatments for cancer patients. <i>The cancer journal from Scientific American</i> 6(1) 2–10. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10696731/&quot;>https://pubmed.ncbi.nlm.nih.gov/10696731</a></p></li><li><p>Zivanovic, O, et al., &amp; Kuhn, WC (2015). HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. <i>International journal of cancer</i> 136(3) 699–708. DOI:<a href=&quot;https://doi.org/10.1002/ijc.29011&quot;>10.1002/ijc.29011</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24895230/&quot;>https://pubmed.ncbi.nlm.nih.gov/24895230</a></p></li><li><p>Zamboni, WC, et al., &amp; Eiseman, JL (2004). Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. <i>Cancer chemotherapy and pharmacology</i> 53(4) 329–336. DOI:<a href=&quot;https://doi.org/10.1007/s00280-003-0719-4&quot;>10.1007/s00280-003-0719-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/14673619/&quot;>https://pubmed.ncbi.nlm.nih.gov/14673619</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XA05;
